Comparing XBiotech (NASDAQ:XBIT) & IN8bio (NASDAQ:INAB)

IN8bio (NASDAQ:INAB) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.

Earnings & Valuation

This table compares IN8bio and XBiotech”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44 million	($4.45)	-0.36
XBiotech	N/A	N/A	-$45.54 million	($1.50)	-1.57

XBiotech is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares IN8bio and XBiotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-111.30%	-88.07%
XBiotech	N/A	-27.80%	-26.67%

Analyst Recommendations

This is a summary of recent ratings for IN8bio and XBiotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1	1	1	0	2.00
XBiotech	1	0	0	0	1.00

IN8bio currently has a consensus target price of $4.00, suggesting a potential upside of 148.45%. Given IN8bio’s stronger consensus rating and higher probable upside, analysts clearly believe IN8bio is more favorable than XBiotech.

Institutional and Insider Ownership

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 15.5% of IN8bio shares are owned by insiders. Comparatively, 30.8% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

IN8bio beats XBiotech on 6 of the 10 factors compared between the two stocks.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager
platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

About XBiotech

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.